JPMorgan Chase crosses substantial holder threshold in Telix Pharmaceuticals

JPMorgan Chase & Co. and its affiliates became a substantial holder in Telix Pharmaceuticals Ltd. on November 12, 2025. Their total voting power in the company reached 5.21%, representing 17,663,335.01 ordinary shares.

The relevant interests are held across various entities, including JPMorgan Chase Bank, N.A. as an investment manager and agent lender, and J.P. Morgan Securities PLC through securities lending agreements and proprietary trading. Noteworthy holdings include 8,589,527 ordinary shares held by JPMorgan Chase Bank, N.A. via securities on loan as agent lender and 3,444,797 ordinary shares by J.P. Morgan Securities PLC subject to a securities lending agreement.

J.P. Morgan Securities Australia Limited also holds a substantial portion, with 4,027,690 ordinary shares through proprietary purchases and sales, and 1,078,579 ordinary shares subject to a securities lending obligation. The associated entities are all subsidiaries of JPMorgan Chase & Co.